Design and methods of a randomised double-blind trial of adding liraglutide to control HbA1c in patients with type 2 diabetes with impaired glycaemic control treated with multiple daily insulin injections (MDI-Liraglutide trial)
Authors:
- 1 February 2015
- journal article
- research article
- Published by Elsevier in Primary Care Diabetes
- Vol. 9 (1) , 15-22
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
This publication has 21 references indexed in Scilit:
- Insulin plus incretin: A glucose-lowering strategy for type 2-diabetesWorld Journal of Diabetes, 2014
- The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetesDiabetologia, 2012
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetologia, 2012
- Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfactionPrimary Care Diabetes, 2012
- Standards of Medical Care in Diabetes—2010Diabetes Care, 2010
- The Impact of Weight Gain on Motivation, Compliance, and Metabolic Control in Patients with Type 2 Diabetes MellitusPostgraduate Medicine, 2009
- Realistic Expectations and Practical Use of Continuous Glucose Monitoring for the EndocrinologistThe Journal of Clinical Endocrinology & Metabolism, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Defining and Reporting Hypoglycemia in DiabetesDiabetes Care, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998